Home / Biotech-Pharma / Hot Watch List After Analysts Reviews- Valeant Pharmaceuticals International (NYSE:VRX), Sage Therapeutics (NASDAQ:SAGE)

Hot Watch List After Analysts Reviews- Valeant Pharmaceuticals International (NYSE:VRX), Sage Therapeutics (NASDAQ:SAGE)

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) [Trend Analysis], stock build up around 6.75% in early session as its gaining volume of 18.74 Million. Analyst’s ratings play a vital role in defining a stock’s performance for the day. Let us check out how WSJ analysts have ranked VRX for quarterly and monthly. For recent position, 4 analysts have ranked the VRX with Buy ratings while 1 ranked overweight. The co for the one-month period was ranked overweight by 1 analyst. Looking over the last month situation it was ranked as “Buy” by 4 analysts. But the stock was ranked Underweight by 1 number of analysts in current phase while overall the consensus rank was for Hold.

Glancing over stock’s performance with EPS trend, the current quarter estimates trends for EPS by pool of analysts was $1.22 and for one month ago was $1.22, as Q1 2017 Trends estimate stands at $1.08, according to WSJ analytic reports. The stock showed weekly upbeat performance of 12.14%, which maintained for the month at 4.24%. Similarly, the positive performance for the quarter recorded as -11.22% and for the year was -82.49%, while the YTD performance remained at 10.06%. VRX has Average True Range for 14 days of 0.65.

Sage Therapeutics, Inc. (NASDAQ:SAGE) [Trend Analysis] pretends to be active mover, stock jumped up around 2.53% to traded at $54.33. The liquidity measure in recent quarter results of the company was recorded 19.50 as current ratio. (Read Latest [Free Analytic] Facts on NASDAQ:SAGE and Be Updated)

Sage Therapeutics reported on Monday that positive results from a small, mid-stage study of a drug for major depressive disorder, sending shares of the fast-growing Cambridge company up more than 12 percent. Sage (NASDAQ:SAGE), a 136-employee biotech located in the Athenaeum building near Kendall Square, said that the 13-patient, Phase 2 study had met its primary goals. The treatment, called SAGE-217, was found to be generally safe and well-tolerated, and patients on average saw a reduction in their depressive symptoms, the company said.

For latest Market Updates Subscribes Here

 

About Steve Hart

Steve Hart is a longtime business journalist who has covered everything from municipal bonds to management, major banks and MBA programs. Prior to becoming a writer at Seneca Globe News, Steve Hart was a securities analyst and a budget and fiscal analyst. Steve can be reached at steve.hart@senecaglobe.com

Leave a Reply

Your email address will not be published. Required fields are marked *